Gastric mucosa alterations in first-degree relatives of gastric cancer patients.

BACKGROUND First-degree relatives of gastric cancer patients have an increased risk of developing such neoplasia, and several alterations in gastric mucosa of these subjects have been described. On the other hand, both gastric cell hyperproliferation and abnormalities of adhesion molecules have been involved in gastric carcinogenesis. We studied gastric mucosa alterations in first-degree relatives of gastric cancer patients. PATIENTS AND METHODS This prospective, case-controlled study enrolled 39 first-degree relatives of gastric cancer patients and 39 matched controls. Biopsy specimens obtained at endoscopy were used to assess epithelial cell proliferation plus E-cadherin and beta-catenin expression by immunohistochemical methods. H. pylori infection was assessed by histology and a rapid urease test. RESULTS Gastric epithelial cell proliferation values were not significantly different between the patient and control groups. H. pylori infection significantly increased cell proliferation values both in patients and in controls, without a significant difference between the two groups. Moreover, cell proliferation values were significantly higher in cases harboring intestinal metaplasia than in those without it. Alterations of the adhesion molecules were described exclusively in those patients harboring intestinal metaplasia. In detail, a reduction of both E-cadherin and beta-catenin expression was observed in 8 (67%) out of 12 first-degree relatives and in 6 (67%) out of 9 controls with intestinal metaplasia (p = 0.4). These alterations were similarly distributed between H. pylori infected and uninfected cases. CONCLUSION Our data showed that a family history of gastric cancer itself is not associated with gastric cell hyperproliferation. However, both cell hyperproliferation and alterations of adhesion molecules have been detected in those patients with intestinal metaplasia.

[1]  M. Plummer,et al.  International agency for research on cancer. , 2020, Archives of pathology.

[2]  A. Vecchione,et al.  Relationship between beta-catenin expression and epithelial cell proliferation in gastric mucosa with intestinal metaplasia. , 2005, World journal of gastroenterology.

[3]  C. Hassan,et al.  Alteration of E-cadherin expression in gastric mucosa: role of intestinal metaplasia and Helicobacter pylori infection. , 2004, Anticancer research.

[4]  C. Gulmann,et al.  Adenomatous Polyposis Coli Gene, &bgr;-Catenin, and E-Cadherin Expression in Proximal and Distal Gastric Cancers and Precursor Lesions: An Immunohistochemical Study Using Tissue Microarrays , 2003, Applied immunohistochemistry & molecular morphology : AIMM.

[5]  Z. Tulassay,et al.  Superoxide-dismutase activity of the gastric mucosa in patients with Helicobacter pylori infection. , 2003, Anticancer research.

[6]  G. Nardone Molecular basis of gastric carcinogenesis , 2003 .

[7]  I. Ng,et al.  Deregulation of E‐cadherin–catenin complex in precancerous lesions of gastric adenocarcinoma , 2003, Journal of gastroenterology and hepatology.

[8]  Yongning Zhou,et al.  Expression of E-cadherin and beta-catenin in gastric carcinoma and its correlation with the clinicopathological features and patient survival. , 2002, World journal of gastroenterology.

[9]  J. Moon,et al.  Role of Helicobacter pylori infection among offspring or siblings of gastric cancer patients , 2002, International journal of cancer.

[10]  R. Seruca,et al.  Different patterns of β‐catenin expression in gastric carcinomas: relationship with clinicopathological parameters and prognostic outcome , 2002, Histopathology.

[11]  Leif E. Peterson,et al.  Histological patterns of gastritis in H. pylori-infected individuals with a family history of gastric cancer , 2002, American Journal of Gastroenterology.

[12]  H. Yatsuya,et al.  Family history and the risk of stomach cancer death in Japan: Differences by age and gender , 2002, International journal of cancer.

[13]  C. Moskaluk,et al.  Inactivation of the E-Cadherin Gene in Sporadic Diffuse-Type Gastric Cancer , 2001, Modern Pathology.

[14]  L. Hansson,et al.  Helicobacter pylori in gastric cancer established by CagA immunoblot as a marker of past infection. , 2001, Gastroenterology.

[15]  H. Grabsch,et al.  Different patterns of β‐catenin expression in gastric carcinomas: relationship with clinicopathological parameters and prognostic outcome , 2001, Histopathology.

[16]  C. Caldas,et al.  Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. , 2001, The New England journal of medicine.

[17]  Ming-Tsan Lin,et al.  Immunohistochemical Evaluation of Cadherin and Catenin Expression in Early Gastric Carcinomas: Correlation with Clinicopathologic Characteristics and Helicobacter pylori Infection , 2001, Oncology.

[18]  D. Spina,et al.  Cell proliferation, cell death, E-cadherin, metalloproteinase expression and angiogenesis in gastric cancer precursors and early cancer of the intestinal type. , 2001, International journal of oncology.

[19]  Ç. Şiviloḡlu,et al.  Stomach cancer history in the siblings of patients with gastric carcinoma , 2000, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[20]  G. Nardone Risk factors for cancer development in Helicobacter pylori gastritis. , 2000, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[21]  C. Hassan,et al.  Ascorbic acid and intestinal metaplasia in the stomach: a prospective, randomized study , 2000, Alimentary pharmacology & therapeutics.

[22]  P. Malfertheiner,et al.  Expression of transforming growth factor beta-1 in gastric cancer and in the gastric mucosa of first-degree relatives of patients with gastric cancer , 2000, British Journal of Cancer.

[23]  P. Malfertheiner,et al.  α-Catenin expression is decreased in human gastric cancers and in the gastric mucosa of first degree relatives , 2000, Gut.

[24]  Jun Yu,et al.  Frequency of TPR‐MET rearrangement in patients with gastric carcinoma and in first‐degree relatives , 2000, Cancer.

[25]  A. Vecchione,et al.  Gastric Epithelial Cell Proliferation in Patients with Liver Cirrhosis , 2000, Digestive Diseases and Sciences.

[26]  C. Stegmaier,et al.  Individual and joint contribution of family history and Helicobacter pylori infection to the risk of gastric carcinoma , 2000, Cancer.

[27]  J. Ferlay,et al.  Erratum: Estimates of the worldwide mortality from 25 cancers in 1990. Int. J. Cancer, 83, 18–29 (1999). , 1999, International journal of cancer.

[28]  J. Ferlay,et al.  Estimates of the worldwide mortality from 25 cancers in 1990 , 1999, International journal of cancer.

[29]  M. Stolte,et al.  Helicobacter pylori gastritis of the gastric cancer phenotype in relatives of gastric carcinoma patients. , 1999, European journal of gastroenterology & hepatology.

[30]  Tytgat,et al.  Loss of E‐cadherin expression in early gastric cancer , 1999, Histopathology.

[31]  P. Guilford E-cadherin downregulation in cancer: fuel on the fire? , 1999, Molecular medicine today.

[32]  Jacques Ferlay,et al.  Estimates of the worldwide incidence of 25 major cancers in 1990 , 1999, International journal of cancer.

[33]  M. Stolte,et al.  Increased cell proliferation of the gastric mucosa in first‐degree relatives of gastric carcinoma patients , 1998, Cancer.

[34]  R. Hunt,et al.  Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. , 1998, Gastroenterology.

[35]  D. O’Toole,et al.  H pylori infection is associated with downregulation of E-cadherin, a molecule involved in epithelial cell adhesion and proliferation control. , 1998, Journal of clinical pathology.

[36]  F. Pierconti,et al.  Epithelial-cell apoptosis and proliferation in Helicobacter pylori-related chronic gastritis. , 1998, Italian journal of gastroenterology and hepatology.

[37]  E. Ierardi,et al.  Effect of Helicobacter pylori eradication on intestinal metaplasia and gastric epithelium proliferation. , 1997, Italian journal of gastroenterology and hepatology.

[38]  W. Birchmeier,et al.  Prognostic value of E‐cadherin expression in 413 gastric carcinomas , 1996, International journal of cancer.

[39]  C. O'Morain,et al.  Gastric epithelial cell kinetics in the progression from normal mucosa to gastric carcinoma. , 1996, Gut.

[40]  C. O'Morain,et al.  Helicobacter pylori and gastric cancer. , 1995, Italian journal of gastroenterology and hepatology.

[41]  J. Parsonnet Helicobacter pylori and gastric cancer. , 1993, Gastroenterology clinics of North America.

[42]  C. la Vecchia,et al.  Family history and the risk of stomach and colorectal cancer , 1992, Cancer.

[43]  R. Sassatelli,et al.  Familial occurrence of gastric cancer in the 2‐year experience of a population‐based registry , 1990, Cancer.

[44]  R. P. Blankfield,et al.  Helicobacter pylori infection and the development of gastric cancer. , 2001, The New England journal of medicine.

[45]  T. Devereux,et al.  Loss of E-cadherin expression in gastric intestinal metaplasia and later stage p53 altered expression in gastric carcinogenesis. , 2001, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[46]  L. Murray,et al.  Increased prevalence of precancerous changes in relatives of gastric cancer patients: critical role of H. pylori. , 2000, Gastroenterology.

[47]  L. Sobin,et al.  Family history and risk of stomach cancer in Warsaw, Poland. , 1999, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[48]  S. Jordan,et al.  Abnormal immunoreactivity of the E-cadherin-catenin complex in gastric carcinoma: relationship with patient survival. , 1997, Gastroenterology.

[49]  G. Stevenson,et al.  Infection with Helicobacter pylori. , 1996, AJR. American journal of roentgenology.

[50]  J. Fraumeni,et al.  Family history and risk of stomach cancer in Italy. , 1994, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.